Clinical Trial Update: DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC [Phase 3]

View source ↗

Summary

Phase 3 trial update for DV in combination with Bacillus Calmette-Guérin in HER2-expressing, BCG-naïve high-risk non-muscle invasive bladder cancer, currently n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (Bacillus Calmette-Guérin)
• DV

Snippet

Sponsor: Fudan University | Conditions: Bladder (Urothelial, Transitional Cell) Cancer, NMIBC | Phase 3 | Status: NOT_YET_RECRUITING